

Hadine Joffe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5763013/publications.pdf>

Version: 2024-02-01

137
papers

7,318
citations

46984

47
h-index

60583

81
g-index

137
all docs

137
docs citations

137
times ranked

6508
citing authors

#	ARTICLE	IF	CITATIONS
1	Vasomotor symptoms in midlife women with incident breast cancer: pink SWAN. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 125-135.	1.1	2
2	Brain-derived neurotrophic factor and mood in perimenopausal depression. <i>Journal of Affective Disorders</i> , 2022, 300, 145-149.	2.0	2
3	A double-blind, randomized, placebo-controlled trial of suvorexant for the treatment of vasomotor symptom-associated insomnia disorder in midlife women. <i>Sleep</i> , 2022, 45, .	0.6	6
4	Enrollment of female participants in United States drug and device phase 1&2 clinical trials between 2016 and 2019. <i>Contemporary Clinical Trials</i> , 2022, 115, 106718.	0.8	22
5	A hormonal therapy for menopausal women with MS: A phase Ib/IIa randomized controlled trial. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103747.	0.9	5
6	NAMS 2021 Utian Translational Science Symposium September 2021, Washington, DC Charting the path to health in midlife and beyond: the biology and practice of wellness. <i>Menopause</i> , 2022, 29, 504-513.	0.8	0
7	P688. Evoked Subjective and Hypothalamic-Pituitary-Adrenal (HPA) Axis Stress Responses in Non-Depressed Midlife Women: Relationship to Vasomotor Symptom Persistence and Insomnia. <i>Biological Psychiatry</i> , 2022, 91, S369.	0.7	0
8	Sleep Fragmentation and Estradiol Suppression Decrease Fat Oxidation in Premenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3167-e3176.	1.8	4
9	Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 53-62.	1.1	15
10	Associations between sleep and cognitive performance in a racially/ethnically diverse cohort: the Study of Women's Health Across the Nation. <i>Sleep</i> , 2021, 44, .	0.6	9
11	Plasma androgens and the presence and course of depression in a large cohort of women. <i>Translational Psychiatry</i> , 2021, 11, 124.	2.4	7
12	Screening for Depression in Younger Breast Cancer Survivors: Outcomes From Use of the 9-item Patient Health Questionnaire. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab017.	1.4	8
13	Menopausal Vasomotor Symptoms and Risk of Incident Cardiovascular Disease Events in SWAN. <i>Journal of the American Heart Association</i> , 2021, 10, e017416.	1.6	56
14	At menopause, what comes first: the sleepless chicken or the sex?. <i>Menopause</i> , 2021, 28, 606-607.	0.8	1
15	A core outcome set for vasomotor symptoms associated with menopause: the COMMA (Core Outcomes) Tj ETQq1_1_0.784314 rgBT 0.8 21	0.8	21
16	Predictors of irritability symptoms in mildly depressed perimenopausal women. <i>Psychoneuroendocrinology</i> , 2021, 126, 105128.	1.3	14
17	Lowered progesterone metabolite excretion and a variable LH excretion pattern are associated with vasomotor symptoms but not negative mood in the early perimenopausal transition: Study of Women's Health Across the Nation. <i>Maturitas</i> , 2021, 147, 26-33.	1.0	1
18	Effect of Experimentally Induced Sleep Fragmentation and Hypoestrogenism on Fasting Nutrient Utilization in Pre-Menopausal Women. <i>Journal of the Endocrine Society</i> , 2021, 5, A774-A774.	0.1	1

#	ARTICLE	IF	CITATIONS
19	Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. <i>Clinical Cancer Research</i> , 2021, 27, 4311-4324.	3.2	44
20	COVID-19 Threatens Progress Toward Gender Equity Within Academic Medicine. <i>Academic Medicine</i> , 2021, 96, 813-816.	0.8	88
21	What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. <i>Gynecologic Oncology</i> , 2021, 161, 527-534.	0.6	9
22	Prescription medications for sleep disturbances among midlife women during 2 years of follow-up: a SWAN retrospective cohort study. <i>BMJ Open</i> , 2021, 11, e045074.	0.8	4
23	Sleep and endocrine therapy in breast cancer. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2021, 18, 165-170.	0.6	7
24	Influence of the menopausal transition on polysomnographic sleep characteristics: a longitudinal analysis. <i>Sleep</i> , 2021, 44, .	0.6	8
25	Targeting Depressive Symptoms in Younger Breast Cancer Survivors: The Pathways to Wellness Randomized Controlled Trial of Mindfulness Meditation and Survivorship Education. <i>Journal of Clinical Oncology</i> , 2021, 39, 3473-3484.	0.8	29
26	Sex and Gender Differences in Health. <i>Annals of Internal Medicine</i> , 2021, 174, 143-144.	2.0	1
27	Longitudinal Association Between Depressive Symptoms and Multidimensional Sleep Health: The SWAN Sleep Study. <i>Annals of Behavioral Medicine</i> , 2021, 55, 641-652.	1.7	13
28	Hypothalamic-pituitary-adrenal axis, subjective, and thermal stress responses in midlife women with vasomotor symptoms. <i>Menopause</i> , 2021, 28, 439-443.	0.8	4
29	Elinzanetant (NT-814): a novel, non-hormonal dual NK-1,3 receptor antagonist for the treatment of vasomotor symptoms - key findings from the Phase 2 SWITCH-1 study. <i>Maturitas</i> , 2021, 152, 71.	1.0	0
30	Identifying women who share patterns of reproductive hormones, vasomotor symptoms, and sleep maintenance problems across the menopause transition: group-based multi-trajectory modeling in the Study of Women's Health Across the Nation. <i>Menopause</i> , 2021, 28, 126-134.	0.8	8
31	Association of Use of Oral Contraceptives With Depressive Symptoms Among Adolescents and Young Women. <i>JAMA Psychiatry</i> , 2020, 77, 52.	6.0	65
32	Impact of Estradiol Variability and Progesterone on Mood in Perimenopausal Women With Depressive Symptoms. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e642-e650.	1.8	27
33	Does midlife aging impact women's sleep duration, continuity, and timing?: A longitudinal analysis from the Study of Women's Health Across the Nation. <i>Sleep</i> , 2020, 43, .	0.6	16
34	Multidimensional sleep health is not cross-sectionally or longitudinally associated with adiposity in the Study of Women's Health Across the Nation (SWAN). <i>Sleep Health</i> , 2020, 6, 790-796.	1.3	18
35	Sex and Gender Differences in Health: What the COVID-19 Pandemic Can Teach Us. <i>Annals of Internal Medicine</i> , 2020, 173, 385-386.	2.0	119
36	BDNF and Mood in Perimenopausal Depression. <i>Biological Psychiatry</i> , 2020, 87, S368-S369.	0.7	0

#	ARTICLE	IF	CITATIONS
37	OR11-03 NT-814, a Non-Hormonal Dual Neurokinin 1,3 Receptor Antagonist Markedly Improves Vasomotor Symptoms in Post-Menopausal Women; Results of a Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Study (SWITCH-1). <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	7
38	Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. <i>Menopause</i> , 2020, 27, 498-505.	0.8	41
39	Workshop on normal reference ranges for estradiol in postmenopausal women: commentary from The North American Menopause Society on low-dose vaginal estrogen therapy labeling. <i>Menopause</i> , 2020, 27, 611-613.	0.8	5
40	Lights on MsFLASH: a review of contributions. <i>Menopause</i> , 2020, 27, 473-484.	0.8	16
41	Sex, Gender, and Precision Medicine—Reply. <i>JAMA Internal Medicine</i> , 2020, 180, 1129.	2.6	1
42	NAMS 2019 Pre-Meeting Symposium, September 2019, Chicago Illinois: The Perimenopause. <i>Menopause</i> , 2020, 27, 735-745.	0.8	1
43	Clinical Advances in Sex- and Gender-Informed Medicine to Improve the Health of All. <i>JAMA Internal Medicine</i> , 2020, 180, 574.	2.6	132
44	Trajectory analysis of sleep maintenance problems in midlife women before and after surgical menopause: the Study of Women's Health Across the Nation (SWAN). <i>Menopause</i> , 2020, 27, 278-288.	0.8	7
45	Antimullerian Hormone and Impending Menopause in Late Reproductive Age: The Study of Women's Health Across the Nation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1862-e1871.	1.8	66
46	Racial/ethnic disparities in women's sleep duration, continuity, and quality, and their statistical mediators: Study of Women's Health Across the Nation. <i>Sleep</i> , 2019, 42, .	0.6	33
47	Cardiovascular reactivity and psychological hyperarousal in hot flash-associated insomnia disorder. <i>Menopause</i> , 2019, 26, 728-740.	0.8	4
48	Confirmatory factor analysis of the Insomnia Severity Index (ISI) and invariance across race: a pooled analysis of MsFLASH data. <i>Menopause</i> , 2019, 26, 850-855.	0.8	13
49	Psychosocial and health-related risk factors for depressive symptom trajectories among midlife women over 15 years: Study of Women's Health Across the Nation (SWAN). <i>Psychological Medicine</i> , 2019, 49, 250-259.	2.7	21
50	The role of sleep difficulties in the vasomotor menopausal symptoms and depressed mood relationships: an international pooled analysis of eight studies in the InterLACE consortium. <i>Psychological Medicine</i> , 2018, 48, 2550-2561.	2.7	27
51	Should Hormone Therapy Be Used to Prevent Depressive Symptoms During the Menopause Transition?. <i>JAMA Psychiatry</i> , 2018, 75, 125.	6.0	11
52	Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials. <i>Sleep</i> , 2018, 41, .	0.6	67
53	Associations between improvement in genitourinary symptoms of menopause and changes in the vaginal ecosystem. <i>Menopause</i> , 2018, 25, 500-507.	0.8	28
54	Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. <i>Menopause</i> , 2018, 25, 1069-1085.	0.8	122

#	ARTICLE	IF	CITATIONS
55	Sleep, Health, and Metabolism in Midlife Women and Menopause. <i>Obstetrics and Gynecology Clinics of North America</i> , 2018, 45, 679-694.	0.7	40
56	Treatment of Premenstrual Breakthrough of Depression With Adjunctive Oral Contraceptive Pills Compared With Placebo. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 609-614.	0.7	14
57	Lifelong estradiol exposure and risk of depressive symptoms during the transition to menopause and postmenopause. <i>Menopause</i> , 2017, 24, 1351-1359.	0.8	33
58	Sleep Trajectories Before and After the Final Menstrual Period in the Study of Women's Health Across the Nation (SWAN). <i>Current Sleep Medicine Reports</i> , 2017, 3, 235-250.	0.7	40
59	The Risk of Remaining Silent: Addressing the Current Threats to Women's Health. <i>Women's Health Issues</i> , 2017, 27, 621-624.	0.9	8
60	Effects of Yoga and Aerobic Exercise on Actigraphic Sleep Parameters in Menopausal Women with Hot Flashes. <i>Journal of Clinical Sleep Medicine</i> , 2017, 13, 11-18.	1.4	35
61	Nocturnal Hot Flashes: Relationship to Objective Awakenings and Sleep Stage Transitions. <i>Journal of Clinical Sleep Medicine</i> , 2016, 12, 1003-1009.	1.4	23
62	Armodafinil for fatigue associated with menopause. <i>Menopause</i> , 2016, 23, 209-214.	0.8	6
63	Telephone-Based Cognitive Behavioral Therapy for Insomnia in Perimenopausal and Postmenopausal Women With Vasomotor Symptoms. <i>JAMA Internal Medicine</i> , 2016, 176, 913.	2.6	110
64	Independent Contributions of Nocturnal Hot Flashes and Sleep Disturbance to Depression in Estrogen-Deprived Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3847-3855.	1.8	50
65	Patterns of depressive disorders across 13 years and their determinants among midlife women: SWAN mental health study. <i>Journal of Affective Disorders</i> , 2016, 206, 31-40.	2.0	45
66	Hot Flash Frequency and Blood Pressure: Data from the Study of Women's Health Across the Nation. <i>Journal of Women's Health</i> , 2016, 25, 1204-1209.	1.5	47
67	Depressive symptoms across the menopause transition: findings from a large population-based cohort study. <i>Menopause</i> , 2016, 23, 1287-1293.	0.8	48
68	Effects of Testosterone and Estradiol Deficiency on Vasomotor Symptoms in Hypogonadal Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3479-3486.	1.8	13
69	Shifting Paradigms About Hormonal Risk Factors for Postmenopausal Depression. <i>JAMA Psychiatry</i> , 2016, 73, 111.	6.0	6
70	Trajectories of Vasomotor Symptoms and Carotid Intima Media Thickness in the Study of Women's Health Across the Nation. <i>Stroke</i> , 2016, 47, 12-17.	1.0	63
71	Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms. <i>Obstetrics and Gynecology</i> , 2015, 126, 413-422.	1.2	47
72	Concern About the Use of Venlafaxine to Treat Vasomotor Symptoms—Reply. <i>JAMA Internal Medicine</i> , 2015, 175, 658.	2.6	1

#	ARTICLE	IF	CITATIONS
73	Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition. <i>JAMA Internal Medicine</i> , 2015, 175, 531.	2.6	601
74	Ovarian Hormone Fluctuation, Neurosteroids, and HPA Axis Dysregulation in Perimenopausal Depression: A Novel Heuristic Model. <i>American Journal of Psychiatry</i> , 2015, 172, 227-236.	4.0	166
75	Effects of Estradiol and Venlafaxine on Insomnia Symptoms and Sleep Quality in Women with Hot Flashes. <i>Sleep</i> , 2015, 38, 97-108.	0.6	55
76	Algorithm and mobile app for menopausal symptom management and hormonal/non-hormonal therapy decision making. <i>Menopause</i> , 2015, 22, 247-253.	0.8	64
77	Placebo Improvement in Pharmacologic Treatment of Menopausal Hot Flashes. <i>Psychosomatic Medicine</i> , 2015, 77, 167-175.	1.3	32
78	Response to Eskola et al.. <i>American Journal of Psychiatry</i> , 2015, 172, 797-797.	4.0	2
79	Effects of Escitalopram on Markers of Bone Turnover: A Randomized Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1732-E1737.	1.8	20
80	Sexual Function in Women on Estradiol or Venlafaxine for Hot Flashes. <i>Obstetrics and Gynecology</i> , 2014, 124, 233-241.	1.2	27
81	Methods for the design of vasomotor symptom trials. <i>Menopause</i> , 2014, 21, 45-58.	0.8	57
82	Low-Dose Estradiol and the Serotonin-Norepinephrine Reuptake Inhibitor Venlafaxine for Vasomotor Symptoms. <i>JAMA Internal Medicine</i> , 2014, 174, 1058.	2.6	160
83	Menopausal quality of life: RCT of yoga, exercise, and omega-3 supplements. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 210, 244.e1-244.e11.	0.7	66
84	Psychotropic-Induced Hyperprolactinemia: A Clinical Review. <i>Psychosomatics</i> , 2014, 55, 29-36.	2.5	90
85	Objective sleep interruption and reproductive hormone dynamics in the menstrual cycle. <i>Sleep Medicine</i> , 2014, 15, 688-693.	0.8	44
86	Duloxetine for major depressive disorder and daytime and nighttime hot flashes associated with the menopausal transition. <i>Maturitas</i> , 2013, 75, 170-174.	1.0	20
87	Adverse effects of induced hot flashes on objectively recorded and subjectively reported sleep. <i>Menopause</i> , 2013, 20, 905-914.	0.8	45
88	Disparate Rates of New-Onset Depression During the Menopausal Transition in 2 Community-based Populations: Real, or Really Wrong?. <i>American Journal of Epidemiology</i> , 2013, 177, 1148-1156.	1.6	7
89	The Impact of Depot GnRH Agonist on AMH Levels in Healthy Reproductive-Aged Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1961-E1966.	1.8	45
90	A Gonadotropin-Releasing Hormone Agonist Model Demonstrates That Nocturnal Hot Flashes Interrupt Objective Sleep. <i>Sleep</i> , 2013, 36, 1977-1985.	0.6	60

#	ARTICLE	IF	CITATIONS
91	Vasomotor Symptoms and Insulin Resistance in the Study of Women's Health Across the Nation. Obstetrical and Gynecological Survey, 2013, 68, 113-114.	0.2	0
92	Trajectory Clustering of Estradiol and Follicle-Stimulating Hormone During the Menopausal Transition Among Women in the Study of Women's Health Across the Nation (SWAN). Obstetrical and Gynecological Survey, 2013, 68, 361-363.	0.2	3
93	Antidepressant use after discontinuation of hormone therapy. Menopause, 2013, 20, 123-125.	0.8	2
94	Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram. Menopause, 2013, 20, 261-268.	0.8	11
95	Vasomotor Symptoms and Insulin Resistance in the Study of Women's Health Across the Nation. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3487-3494.	1.8	100
96	Trajectory Clustering of Estradiol and Follicle-Stimulating Hormone during the Menopausal Transition among Women in the Study of Women's Health across the Nation (SWAN). Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2872-2880.	1.8	122
97	Metabolic Activity in the Insular Cortex and Hypothalamus Predicts Hot Flashes: An FDG-PET Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3207-3215.	1.8	26
98	Sexual Function in Nondepressed Women Using Escitalopram for Vasomotor Symptoms. Obstetrics and Gynecology, 2012, 119, 527-538.	1.2	22
99	Mood Symptoms After Natural Menopause and Hysterectomy With and Without Bilateral Oophorectomy Among Women in Midlife. Obstetrics and Gynecology, 2012, 119, 935-941.	1.2	45
100	Vasomotor Symptoms and Lipid Profiles in Women Transitioning Through Menopause. Obstetrics and Gynecology, 2012, 119, 753-761.	1.2	88
101	Lifetime History of Depression and Anxiety Disorders as a Predictor of Quality of Life in Midlife Women in the Absence of Current Illness Episodes. Archives of General Psychiatry, 2012, 69, 484.	13.8	37
102	PSYCHOSOCIAL FEATURES ASSOCIATED WITH LIFETIME COMORBIDITY OF MAJOR DEPRESSION AND ANXIETY DISORDERS AMONG A COMMUNITY SAMPLE OF MID-LIFE WOMEN: THE SWAN MENTAL HEALTH STUDY. Depression and Anxiety, 2012, 29, 1050-1057.	2.0	41
103	Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: A randomized controlled trial. Maturitas, 2012, 73, 361-368.	1.0	34
104	Sleep During the Perimenopause: A SWAN Story. Obstetrics and Gynecology Clinics of North America, 2011, 38, 567-586.	0.7	161
105	Increased Estradiol and Improved Sleep, But Not Hot Flashes, Predict Enhanced Mood during the Menopausal Transition. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1044-E1054.	1.8	90
106	Response to Harvey and Kornstein Letter. American Journal of Psychiatry, 2011, 168, 989-990.	4.0	0
107	Longitudinal Follow-Up of Bipolar Disorder in Women With Premenstrual Exacerbation: Findings From STEP-BD. American Journal of Psychiatry, 2011, 168, 386-394.	4.0	53
108	Efficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women. JAMA - Journal of the American Medical Association, 2011, 305, 267.	3.8	199

#	ARTICLE	IF	CITATIONS
109	Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes. <i>Menopause</i> , 2010, 17, 908-916.	0.8	45
110	Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 202, 171.e1-171.e11.	0.7	65
111	Menopause-associated Symptoms and Cognitive Performance: Results From the Study of Women's Health Across the Nation. <i>American Journal of Epidemiology</i> , 2010, 171, 1214-1224.	1.6	143
112	Evaluation and Management of Sleep Disturbance during the Menopause Transition. <i>Seminars in Reproductive Medicine</i> , 2010, 28, 404-421.	0.5	155
113	Introduction. <i>Harvard Review of Psychiatry</i> , 2009, 17, 69-71.	0.9	3
114	A Reproductive Subtype of Depression. <i>Harvard Review of Psychiatry</i> , 2009, 17, 72-86.	0.9	112
115	Gains in Body Fat and Vasomotor Symptom Reporting Over the Menopausal Transition: The Study of Women's Health Across the Nation. <i>American Journal of Epidemiology</i> , 2009, 170, 766-774.	1.6	122
116	Depression is associated with worse objectively and subjectively measured sleep, but not more frequent awakenings, in women with vasomotor symptoms. <i>Menopause</i> , 2009, 16, 671-679.	0.8	73
117	<i>Menstrual Cycle Dysfunction Associated with Neurologic and Psychiatric Disorders</i>. <i>Annals of the New York Academy of Sciences</i> , 2008, 1135, 219-229.	1.8	37
118	Relation of Daily Urinary Hormone Patterns to Vasomotor Symptoms in a Racially/Ethnically Diverse Sample of Midlife Women: Study of Women's Health Across the Nation. <i>Reproductive Sciences</i> , 2007, 14, 786-797.	1.1	16
119	Treatment of Depression and Menopause-Related Symptoms With the Serotonin-Norepinephrine Reuptake Inhibitor Duloxetine. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 943-950.	1.1	81
120	Treatment of Premenstrual Worsening of Depression With Adjunctive Oral Contraceptive Pills. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1954-1962.	1.1	35
121	Reproductive biology and psychotropic treatments in premenopausal women with bipolar disorder. <i>Journal of Clinical Psychiatry</i> , 2007, 68 Suppl 9, 10-5.	1.1	9
122	Valproate Is Associated with New-Onset Oligoamenorrhea with Hyperandrogenism in Women with Bipolar Disorder. <i>Biological Psychiatry</i> , 2006, 59, 1078-1086.	0.7	117
123	Longitudinal Follow-up of Reproductive and Metabolic Features of Valproate-Associated Polycystic Ovarian Syndrome Features: A Preliminary Report. <i>Biological Psychiatry</i> , 2006, 60, 1378-1381.	0.7	50
124	Estrogen therapy selectively enhances prefrontal cognitive processes. <i>Menopause</i> , 2006, 13, 411-422.	0.8	195
125	Physical activity and risk of vasomotor symptoms in women with and without a history of depression. <i>Menopause</i> , 2006, 13, 553-560.	0.8	50
126	Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women. <i>Menopause</i> , 2006, 13, 780-786.	0.8	115

#	ARTICLE	IF	CITATIONS
127	Eszopiclone in Patients With Insomnia During Perimenopause and Early Postmenopause. <i>Obstetrics and Gynecology</i> , 2006, 108, 1402-1410.	1.2	114
128	Sociodemographic predictors of antenatal and postpartum depressive symptoms among women in a medical group practice. <i>Journal of Epidemiology and Community Health</i> , 2006, 60, 221-227.	2.0	489
129	Menstrual Dysfunction Prior to Onset of Psychiatric Illness Is Reported More Commonly by Women With Bipolar Disorder Than by Women With Unipolar Depression and Healthy Controls. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 297-304.	1.1	35
130	Gender differences in bipolar disorder: retrospective data from the first 500 STEP-BD participants. <i>Bipolar Disorders</i> , 2005, 7, 465-470.	1.1	116
131	Menopause and Mood. <i>Clinical Obstetrics and Gynecology</i> , 2004, 47, 576-591.	0.6	20
132	Impact of oral contraceptive pill use on premenstrual mood: Predictors of improvement and deterioration. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 189, 1523-1530.	0.7	124
133	Assessment and treatment of hot flushes and menopausal mood disturbance. <i>Psychiatric Clinics of North America</i> , 2003, 26, 563-580.	0.7	60
134	A Putative Relationship between Valproic Acid and Polycystic Ovarian Syndrome: Implications for Treatment of Women with Seizure and Bipolar Disorders. <i>Harvard Review of Psychiatry</i> , 2003, 11, 99-108.	0.9	13
135	Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. <i>Menopause</i> , 2002, 9, 392-398.	0.8	160
136	An Open Trial of Mirtazapine in Menopausal Women with Depression Unresponsive to Estrogen Replacement Therapy. <i>Journal of Women's Health and Gender-Based Medicine</i> , 2001, 10, 999-1004.	1.7	58
137	Estrogen, serotonin, and mood disturbance: where is the therapeutic bridge?. <i>Biological Psychiatry</i> , 1998, 44, 798-811.	0.7	246